Procarbazine, Lomustine and Vincristine or Temozolomide: Which is the Better Regimen?

Overview

Journal CNS Oncol

Specialty Oncology

Date 2015 Nov 7

PMID 26544062

Citations 14

Authors

Andrew B Lassman

Affiliations

Soon will be listed here.

Abstract

Anaplastic oligodendrogliomas (AOs) are rare brain tumors responsive to chemotherapy with procarbazine, lomustine (CCNU) and vincristine (PCV), especially when harboring 1p19q codeletion. However, with the emergence of temozolomide as an easier to administer and less toxic alternative regimen, PCV fell out of favor. Now, long-term results of two Phase III studies conceived in the 1990s, Radiation Therapy Oncology Group (RTOG) 9402 and European Organisation for Research and Treatment of Cancer (EORTC) 26951, resurrected debate about the potential role of PCV. No adequately powered prospective trial has compared chemotherapy alone with PCV versus temozolomide for newly diagnosed 1p19q codeleted AOs. Available data suggest responses may be both more frequent and more durable with PCV, and survival may be longer. Which regimen is 'better', therefore, depends on the importance of different metrics (i.e., toxicity, complexity, efficacy), and await definitive results from the important ongoing and recently redesigned CODEL international Phase III trial.

Citing Articles

Management of Low-Grade Gliomas.

Diaz M, Pan P Cancer J. 2025; 31(1).

PMID: 39841424 PMC: 11801446. DOI: 10.1097/PPO.0000000000000760.

An introductory review of post-resection chemotherapeutics for primary brain tumors.

McGovern M, Scanlon M, Stanton A, Lucke-Wold B Explor Target Antitumor Ther. 2023; 4(3):537-544.

PMID: 37455829 PMC: 10344890. DOI: 10.37349/etat.2023.00150.

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.

Lassman A, Hoang-Xuan K, Polley M, Brandes A, Cairncross J, Kros J J Clin Oncol. 2022; 40(23):2539-2545.

PMID: 35731991 PMC: 9362869. DOI: 10.1200/JCO.21.02543.

Therapeutic Options in Neuro-Oncology.

Afonso M, Brito M Int J Mol Sci. 2022; 23(10).

PMID: 35628161 PMC: 9140894. DOI: 10.3390/ijms23105351.

Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics.

Skubnik J, Pavlickova V, Ruml T, Rimpelova S Biology (Basel). 2021; 10(9).

PMID: 34571726 PMC: 8468923. DOI: 10.3390/biology10090849.

References

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J . Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2012; 31(3):337-43. PMC: 3732012. DOI: 10.1200/JCO.2012.43.2674. View

Brandes A, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L . Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol. 2006; 24(29):4746-53. DOI: 10.1200/JCO.2006.06.3891. View

van den Bent M, Looijenga L, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L . Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer. 2003; 97(5):1276-84. DOI: 10.1002/cncr.11187. View

Reifenberger J, Reifenberger G, Liu L, James C, WECHSLER W, Collins V . Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994; 145(5):1175-90. PMC: 1887413. View

Peyre M, Cartalat-Carel S, Meyronet D, Ricard D, Jouvet A, Pallud J . Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2010; 12(10):1078-82. PMC: 3018918. DOI: 10.1093/neuonc/noq055. View

Kouwenhoven M, Kros J, French P, Biemond-ter Stege E, Graveland W, Taphoorn M . 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 2006; 42(15):2499-503. DOI: 10.1016/j.ejca.2006.05.021. View

Cairncross J, Macdonald D . Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988; 23(4):360-4. DOI: 10.1002/ana.410230408. View

Ahluwalia M, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher P . Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. J Neurooncol. 2014; 122(1):111-9. DOI: 10.1007/s11060-014-1684-y. View

van den Bent M, Carpentier A, Brandes A, Sanson M, Taphoorn M, Bernsen H . Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of.... J Clin Oncol. 2006; 24(18):2715-22. DOI: 10.1200/JCO.2005.04.6078. View

10.

van den Bent M, Taphoorn M, Brandes A, Menten J, Stupp R, Frenay M . Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003; 21(13):2525-8. DOI: 10.1200/JCO.2003.12.015. View

11.

Levin V, Edwards M, Wright D, Seager M, Schimberg T, Townsend J . Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980; 64(2-3):237-44. View

12.

Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D . Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006; 24(18):2707-14. DOI: 10.1200/JCO.2005.04.3414. View

13.

van den Bent M, Kros J, Heimans J, Pronk L, Van Groeningen C, Krouwer H . Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology. 1998; 51(4):1140-5. DOI: 10.1212/wnl.51.4.1140. View

14.

Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E . Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol. 2007; 61(5):484-90. DOI: 10.1002/ana.21125. View

15.

Mason W, Krol G, DeAngelis L . Low-grade oligodendroglioma responds to chemotherapy. Neurology. 1996; 46(1):203-7. DOI: 10.1212/wnl.46.1.203. View

16.

Cairncross G, MacDonald D, Ludwin S, Lee D, Cascino T, Buckner J . Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994; 12(10):2013-21. DOI: 10.1200/JCO.1994.12.10.2013. View

17.

Vogelbaum M, Berkey B, Peereboom D, MacDonald D, Giannini C, Suh J . Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 2008; 11(2):167-75. PMC: 2718988. DOI: 10.1215/15228517-2008-073. View

18.

Paleologos N, Macdonald D, Vick N, Cairncross J . Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology. 1999; 53(5):1141-3. DOI: 10.1212/wnl.53.5.1141. View

19.

Glass J, Hochberg F, Gruber M, Louis D, Smith D, Rattner B . The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg. 1992; 76(5):741-5. DOI: 10.3171/jns.1992.76.5.0741. View

20.

Cairncross J, Ueki K, Zlatescu M, Lisle D, Finkelstein D, Hammond R . Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998; 90(19):1473-9. DOI: 10.1093/jnci/90.19.1473. View